Isomorphic Labs Raises $5 Billion to Push AI Drugs Toward Trials

Reading Time : 3 minutes

Isomorphic Labs, the drug discovery company spun out of Google DeepMind, has raised $5 billion in a Series C financing co-led by Greenoaks and Sequoia Capital. The round, announced on November 17, also drew participation from Andreessen Horowitz and several new investors, while Alphabet continued to back the company. The raise arrives roughly six months after Isomorphic secured $2.1 billion in a Series B led by Thrive Capital, and it underscores how aggressively investors are funding artificial intelligence applied to medicine. Isomorphic did not disclose its valuation, though Bloomberg had reported that the financing could value the company at about $50 billion.

 

 

The company is led by Demis Hassabis, the DeepMind co-founder whose work on AlphaFold helped earn a Nobel Prize. Isomorphic is attempting to turn that protein-structure technology into a broader engine for discovering and designing drugs. Its IsoDDE platform, according to the company, has produced encouraging preclinical results in internal oncology and immunology programs, as well as in collaborations with pharmaceutical partners. The stated goal is not simply to find a handful of promising molecules, but to build a system capable of producing hundreds of drug candidates each year.

 

 

The financing will fund several fronts at once. Isomorphic plans to continue improving its models, expand a partner network centered on disease biology, and build the clinical development infrastructure required to move laboratory discoveries into human testing. Hassabis has said the company has more than 20 programs underway and intends to broaden beyond small molecules into biologics and other drug modalities. Existing partners include Eli Lilly, Novartis, and Johnson & Johnson, giving the company access to established pharmaceutical development capabilities even as it tries to prove that AI can materially improve the earliest stages of drug discovery.

 

 

The central question is whether Isomorphic can meet its own deadline. In January, Hassabis said the company expected to begin its first clinical trials by the end of 2026, a target now only weeks away. No regulator has yet approved a drug designed by AI, and translating computational predictions into safe, effective therapies remains one of biotechnology’s hardest tests. Still, Hassabis framed the new capital as a way to accelerate progress, saying it would help drive the company’s first therapeutic programs toward clinical trials and deliver tangible benefits for patients.

 

Bénédicte Lin – Brussels, Paris, London, Beijing, Seoul, Bangkok, Tokyo, New York, Taipei, Hong Kong
Bénédicte Lin – Brussels, Paris, London, Beijing, Seoul, Bangkok, Tokyo, New York, Taipei, Hong Kong

 

#IsomorphicLabs #AIDrugDiscovery #Biotech #AlphaFold #Pharma #SeriesC #DrugDevelopment #ArtificialIntelligence #Healthcare #ClinicalTrials